Telix Pharmaceuticals Ltd

Healthcare AU TLX

12.54AUD
-0.19(1.49%)

Last update at 2024-04-17T06:00:00Z

Day Range

12.0112.96
LowHigh

52 Week Range

7.2813.54
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -98.62200M -80.46500M -47.93500M -31.12200M -15.71389M
Minority interest - - - - -
Net income -104.07900M -80.51000M -44.88700M -27.86700M -13.82982M
Selling general administrative 77.32M 34.92M 18.01M 11.28M 8.50M
Selling and marketing expenses 16.19M 5.89M 1.20M 0.31M 0.58M
Gross profit 94.43M 2.35M 2.66M 0.94M 0.20M
Reconciled depreciation 5.38M 5.17M 4.88M 4.24M 0.00697M
Ebit -92.20600M -75.24700M -46.76000M -28.71400M -15.68487M
Ebitda -86.82700M -70.07300M -41.87800M -24.47800M -15.67791M
Depreciation and amortization 5.38M 5.17M 4.88M 4.24M 0.00697M
Non operating income net other - - - - -
Operating income -92.20600M -75.24700M -46.76000M -28.71400M -27.65396M
Other operating expenses 251.00M 103.70M 54.47M 43.74M -
Interest expense 6.42M 5.22M 1.18M 2.41M 0.03M
Tax provision 5.46M 0.04M -3.04800M -3.25500M -1.88407M
Interest income 0.00100M 0.16M 0.07M 2.39M 1.80M
Net interest income -6.69200M -5.21800M -1.10800M -2.31000M 0.30M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.46M 0.04M -3.04800M -3.25500M -1.88407M
Total revenue 155.98M 4.90M 4.68M 3.48M 0.20M
Total operating expenses 189.44M 101.15M 52.44M 41.20M 27.85M
Cost of revenue 61.56M 2.55M 2.02M 2.54M 0.00000M
Total other income expense net -6.41600M -5.21800M -1.17500M -2.40800M 11.94M
Discontinued operations - - - - -
Net income from continuing ops -104.07900M -80.51000M -44.88700M -27.86700M -13.82982M
Net income applicable to common shares -104.07900M -80.51000M -44.88700M -27.86700M -13.83000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 398.30M 255.35M 109.81M 157.82M 102.61M
Intangible assets 104.82M 53.47M 51.63M 54.97M 37.72M
Earning assets - - - - -
Other current assets 7.10M 6.57M 1.43M 1.79M 0.94M
Total liab 249.39M 175.35M 107.66M 78.81M 32.53M
Total stockholder equity 148.91M 80.01M 2.16M 79.02M 70.08M
Deferred long term liab - - - - -
Other current liab 123.01M 68.11M 6.14M 6.29M 3.17M
Common stock 446.27M 370.97M 170.84M 167.06M 115.94M
Capital stock 446.27M 370.97M 170.84M 167.06M 115.94M
Retained earnings -263.66500M -272.81500M -173.47100M -92.96100M -48.07400M
Other liab - 79.98M 67.77M 57.41M 20.26M
Good will 4.85M 5.52M 4.10M 4.22M 4.22M
Other assets - 3.97M 0.21M 0.18M 0.08M
Cash 123.24M 116.33M 22.04M 77.94M 44.60M
Cash and equivalents - - - - -
Total current liabilities 157.41M 85.56M 37.98M 19.96M 10.62M
Current deferred revenue 112.02M - 19.32M 7.09M -
Net debt -105.79200M -105.88300M -19.49800M -75.73800M -42.46700M
Short term debt 1.56M 0.64M 0.63M 0.77M 0.49M
Short long term debt 0.96M - 0.02M 0.26M 0.47M
Short long term debt total 17.45M 10.45M 2.54M 2.21M 2.13M
Other stockholder equity - -0.56200M 4.79M 4.92M 2.21M
Property plant equipment - 18.84M 6.33M 4.82M 1.90M
Total current assets 224.85M 173.23M 47.54M 93.63M 58.68M
Long term investments 12.26M - - - -
Net tangible assets - 21.02M -53.57100M 19.83M 28.13M
Short term investments - - - - -
Net receivables 64.78M 39.35M 19.42M 12.40M 12.07M
Long term debt 8.21M 3.31M 0.00000M 0.10M 0.29M
Inventory 17.31M 8.48M 3.45M 0.63M 0.54M
Accounts payable 32.84M 16.81M 11.88M 5.81M 6.96M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -33.69200M -18.15000M 4.79M 4.92M 2.21M
Additional paid in capital - - - - -
Common stock total equity - - - 167.06M 115.94M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.17M 0.33M 0.21M 0.18M 0.08M
Deferred long term asset charges - - - - -
Non current assets total 173.45M 82.12M 62.27M 64.19M 43.93M
Capital lease obligations 8.27M 7.13M 2.52M 1.85M 1.37M
Long term debt total - 9.80M 1.91M 1.44M 1.64M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -25.48900M -16.99700M -2.72600M -1.09100M -0.46800M
Change to liabilities - 27.64M 4.79M 32.42M 2.98M
Total cashflows from investing activities - -16.99700M -2.72600M -1.09100M -0.46800M
Net borrowings - 1.74M -0.93600M -0.90400M -1.16700M
Total cash from financing activities 10.19M 174.96M 2.85M 34.12M 42.72M
Change to operating activities - -3.68600M 2.60M -0.19300M 0.20M
Net income 5.21M -104.07900M -80.51000M -44.88700M -27.86700M
Change in cash 6.91M 94.29M -55.90800M 33.35M 18.83M
Begin period cash flow 116.33M 22.04M 77.94M 44.60M 25.77M
End period cash flow 123.24M 116.33M 22.04M 77.94M 44.60M
Total cash from operating activities 23.88M -63.97000M -59.32800M 1.96M -23.33300M
Issuance of capital stock 6.65M 181.04M 3.78M 35.15M 45.25M
Depreciation 6.92M 5.38M 5.17M 4.88M 4.24M
Other cashflows from investing activities - -3.13600M -1.38700M -0.44700M -0.44700M
Dividends paid - -168.40800M - -34.48900M -
Change to inventory -9.63600M -5.02300M -2.82100M -0.09100M 0.10M
Change to account receivables -27.38200M -19.93400M -7.19200M -0.32800M -3.63500M
Sale purchase of stock - -7.81600M 3.78M -0.13000M 45.25M
Other cashflows from financing activities 9.29M 180.96M -0.59600M 34.12M -1.58800M
Change to netincome - 35.74M 18.64M 10.15M 0.66M
Capital expenditures 10.79M 13.86M 1.34M 0.32M 0.47M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -33.50600M -1.00700M -2.63000M 31.81M -0.36100M
Stock based compensation - 8.11M 1.32M 2.35M 1.27M
Other non cash items 45.26M 41.00M 31.52M 18.66M -0.61000M
Free cash flow 13.09M -77.83100M -60.66700M 1.64M -23.80100M

Fundamentals

  • Previous Close 12.73
  • Market Cap4027.20M
  • Volume990477
  • P/E Ratio621.50
  • Dividend Yield-%
  • EBITDA57.17M
  • Revenue TTM502.55M
  • Revenue Per Share TTM1.57
  • Gross Profit TTM 98.54M
  • Diluted EPS TTM0.02

Announcements

ASX : TLX announces annual results, emphasizing shareholder value with a final dividend declaration.
View all ASX announcements Click Here

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TLX
Telix Pharmaceuticals Ltd
-0.19 1.49% 12.54 621.50 60.98 8.01 27.00 7.86 169.90
CSL
CSL Ltd
-2.08 0.76% 272.62 36.09 31.25 9.56 5.23 10.85 34.71
NEU
Neuren Pharmaceuticals Ltd
0.06 0.31% 19.51 17.27 38.31 11.59 13.12 10.62 12.37
MSB
Mesoblast Ltd
-0.02 2.60% 0.75 - 769.23 118.24 1.15 127.30 -19.5193
CUV
Clinuvel Pharmaceuticals Ltd
-0.05 0.33% 15.15 26.81 18.55 9.37 4.29 7.30 11.68

Reports Covered

Stock Research & News

Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Telix Pharmaceuticals Ltd

55 Flemington Road, North Melbourne, VIC, Australia, 3051

Key Executives

Name Title Year Born
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA Co-Founder, Group MD, CEO & Exec. Director 1975
Dr. Andreas Kluge M.D., Ph.D. Chief Medical Advisor & Director NA
Mr. Darren Smith B.Bus., FCPA, M.B.A. Group Chief Financial Officer 1965
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) Chief Scientist NA
Ms. Kyahn Williamson Sr. VP of Corp. Communications & Investor Relations NA
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. Sr. VP of Global Governance, Risk & Compliance NA
Ms. Lena Moran-Adams Gen. Counsel NA
Ms. Amanda Griffin Communications Mang. NA
Mr. Christian Davis VP Sales and Marketing, EMEA NA
Ms. Meredith Crowe Interim Sr. VP of Global People & Culture NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).